MarketCap
Royalty Pharma plc RPRX
€ 54.25
2.25%
Facebook
X
Telegram
Land |
 Vereinigte Staaten |
IPO-Jahr |
2020 |
Branche |
Pharmaeinzelhändler |
Börse |
NASDAQ GLOBAL |
Anteile |
430 M |
Marktkapitalisierung |
$ 26.2 B |
EBITDA (LTM) |
$ 1.56 B |
P/E (LTM) |
35.731844 |
P/S (LTM) |
11.559227 |
EPS (LTM) |
1.79 |
Andere Aktien der Branche "Pharmaeinzelhändler"
| Name | Preis | % 24h | Marktkapitalisierung | Börse | Land | |
|---|---|---|---|---|---|---|
 |
Turning Point Therapeutics
TPTX
|
- | -0.13 % | $ 3.73 B | Nasdaq Global Select Market,SPB | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
$ 295.54 | 1.19 % | $ 5.72 B | Nasdaq Global Select Market,SPB | USA |
 |
Epizyme
EPZM
|
- | - | $ 249 M | Nasdaq Global Select Market | USA |
 |
Longeveron
LGVN
|
$ 1.39 | 0.81 % | $ 24.4 B | Nasdaq Global Select Market | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 25.87 | 1.3 % | $ 1.21 B | Nasdaq Global Select Market | USA |
 |
Annovis Bio
ANVS
|
$ 0.99 | 0.95 % | $ 20.3 M | NYSE American | USA |
 |
Forward Pharma A/S
FWP
|
- | -0.75 % | $ 18.7 M | Nasdaq Capital Market |  Danmark |
 |
Regulus Therapeutics
RGLS
|
- | - | $ 155 M | Nasdaq Global Select Market | USA |
 |
Eli Lilly and Company
LLY
|
$ 1 257.03 | 0.42 % | $ 1.13 T | NYSE,SPB | USA |
 |
Marinus Pharmaceuticals
MRNS
|
- | - | $ 29.6 M | Nasdaq Global Select Market | USA |
 |
NeuBase Therapeutics
NBSE
|
- | -1.56 % | $ 12.3 M | Nasdaq Global Select Market | USA |
 |
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | USA |
 |
Scopus BioPharma
SCPS
|
- | -48.37 % | $ 3.71 M | Nasdaq Global Select Market | USA |
 |
scPharmaceuticals
SCPH
|
- | - | $ 218 M | Nasdaq Global Select Market | USA |
 |
Athersys
ATHX
|
- | 3.77 % | $ 22.4 M | Nasdaq Capital Market | USA |
 |
Amneal Pharmaceuticals
AMRX
|
$ 19.18 | 0.42 % | $ 6.01 B | NYSE | USA |
 |
Inozyme Pharma
INZY
|
- | - | $ 207 M | Nasdaq Global Select Market | USA |
 |
Sigilon Therapeutics
SGTX
|
- | - | $ 728 M | Nasdaq Global Select Market | USA |
 |
Rubius Therapeutics
RUBY
|
- | -33.55 % | $ 7.81 M | Nasdaq Global Select Market | USA |
 |
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | USA |
 |
TRACON Pharmaceuticals
TCON
|
- | -1.38 % | $ 46.8 M | Nasdaq Capital Market | USA |
 |
Revance Therapeutics
RVNC
|
- | - | $ 309 M | Nasdaq Global Select Market | USA |
 |
Lipocine
LPCN
|
$ 1.56 | 4.32 % | $ 8.5 M | Nasdaq Global Select Market | USA |
 |
Sierra Oncology
SRRA
|
- | -0.05 % | $ 1.34 B | Nasdaq Global Select Market |  Canada |
 |
Vaccinex
VCNX
|
- | -61.37 % | $ 654 K | Nasdaq Global Select Market | USA |
 |
Forma Therapeutics Holdings
FMTX
|
- | - | $ 958 M | Nasdaq Global Market | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
- | -9.72 % | $ 5.89 M | Nasdaq Capital Market | USA |
 |
Blueprint Medicines Corporation
BPMC
|
- | - | $ 8.14 B | Nasdaq Global Select Market,SPB | USA |
 |
Paratek Pharmaceuticals
PRTK
|
- | - | $ 121 M | Nasdaq Global Market | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
- | -14.27 % | $ 1.7 M | Nasdaq Global Market |  Singapore |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | USA |
 |
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | USA |
 |
Nabriva Therapeutics plc
NBRV
|
- | - | $ 4.55 M | Nasdaq Global Select Market |  Irlanda |
 |
NGM Biopharmaceuticals
NGM
|
- | - | $ 127 M | Nasdaq Global Select Market,SPB | USA |
 |
Unity Biotechnology
UBX
|
- | -33.41 % | $ 3.37 M | Nasdaq Global Select Market | USA |
 |
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | USA |
 |
Titan Pharmaceuticals
TTNP
|
- | -3.76 % | $ 3.47 M | Nasdaq Capital Market | USA |
 |
iTeos Therapeutics
ITOS
|
- | - | $ 411 M | Nasdaq Global Market | USA |
 |
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | USA |
 |
TCR2 Therapeutics
TCRR
|
- | - | $ 58.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Liquidia Corporation
LQDA
|
$ 34.35 | 2.47 % | $ 2.96 B | Nasdaq Capital Market | USA |
 |
CymaBay Therapeutics
CBAY
|
- | - | $ 3.45 B | Nasdaq Global Select Market | USA |
 |
TFF Pharmaceuticals
TFFP
|
- | -60.05 % | $ 125 K | Nasdaq Global Select Market | USA |
 |
Theratechnologies
THTX
|
- | - | $ 83.9 M | Nasdaq Capital Market | Canada |
 |
Timber Pharmaceuticals
TMBR
|
- | - | $ 717 K | NYSE American | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M | Nasdaq Global Select Market |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
- | - | $ 521 M | Nasdaq Capital Market | USA |
 |
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | USA |
 |
Axcella Health
AXLA
|
- | -16.42 % | $ 249 M | Nasdaq Global Market | USA |